



Measles & Rubella Publications

1. Thompson KM, Badizadegan K. Health economic analyses of secondary vaccine effects: a systematic review and policy insights. *Expert Rev Vaccines* 2022; 1-16. doi:10.1080/14760584.2022.2017287. <https://www.tandfonline.com/doi/full/10.1080/14760584.2022.2017287>. Epub 20220112.
2. Badizadegan K, Goodson JL, Rota PA, Thompson KM. The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization. *Expert Rev Vaccines* 2020; 19(2): 175-94. doi:10.1080/14760584.2020.1732215. <https://www.ncbi.nlm.nih.gov/pubmed/32182145>. Epub 2020 Mar 17.
3. Thompson KM. What will it take to end fatalities from measles? *Lancet Glob Health* 2019; 7(4): e394-e5. doi:10.1016/s2214-109x(19)30050-6. <https://www.ncbi.nlm.nih.gov/pubmed/30797736>
4. Thompson KM, Badizadegan ND. Modeling the transmission of measles and rubella to support global management policy analyses and eradication investment cases. *Risk Anal* 2017; 37(6): 1109-31. doi:10.1111/risa.12831. <https://www.ncbi.nlm.nih.gov/pubmed/28561947>
5. Thompson KM. What will it take to end human suffering from measles? *Lancet Infect Dis* 2017; 17(10): 1013-4. doi:10.1016/s1473-3099(17)30451-6. <https://www.ncbi.nlm.nih.gov/pubmed/28807626>
6. Thompson KM. Modeling and managing the risks of measles and rubella: a global perspective part II. *Risk Anal* 2017; 37(6): 1041-51. doi:10.1111/risa.12823. <https://www.ncbi.nlm.nih.gov/pubmed/28471528>
7. Thompson KM, Simons EA, Badizadegan K, Reef SE, Cooper LZ. Characterization of the risks of adverse outcomes following rubella infection in pregnancy. *Risk Anal* 2016; 36(7): 1315-31. doi:10.1111/risa.12264. <https://www.ncbi.nlm.nih.gov/pubmed/25100307>
8. Thompson KM, Odahowski CL, Goodson JL, Reef SE, Perry RT. Synthesis of evidence to characterize national measles and rubella exposure and immunization histories. *Risk Anal* 2016; 36(7): 1427-58. doi:10.1111/risa.12454. <https://www.ncbi.nlm.nih.gov/pubmed/26249328>
9. Thompson KM, Odahowski CL. Systematic review of health economic analyses of measles and rubella immunization interventions. *Risk Anal* 2016; 36(7): 1297-314. doi:10.1111/risa.12331. <https://www.ncbi.nlm.nih.gov/pubmed/25545778>
10. Thompson KM, Odahowski CL. Systematic review of measles and rubella serology studies. *Risk Anal* 2016; 36(7): 1459-86. doi:10.1111/risa.12430. <https://www.ncbi.nlm.nih.gov/pubmed/26077609>
11. Thompson KM, Odahowski CL. The costs and valuation of health impacts of measles and rubella risk management policies. *Risk Anal* 2016; 36(7): 1357-82. doi:10.1111/risa.12459. <https://www.ncbi.nlm.nih.gov/pubmed/26249331>
12. Thompson KM, Logan GE, Florida SRT. Characterization of heterogeneity in childhood immunization coverage in central Florida using immunization registry data. *Risk Anal* 2016; 36(7): 1418-26. doi:10.1111/risa.12424. <https://www.ncbi.nlm.nih.gov/pubmed/26033542>
13. Thompson KM, Kisjes KH. Modeling measles transmission in the North American Amish and options for outbreak response. *Risk Anal* 2016; 36(7): 1404-17. doi:10.1111/risa.12440. <https://www.ncbi.nlm.nih.gov/pubmed/26103154>
14. Thompson KM, Duintjer Tebbens RJ. Framework for optimal global vaccine stockpile design for vaccine-preventable diseases: application to measles and cholera vaccines as contrasting examples. *Risk Anal* 2016; 36(7): 1487-509. doi:10.1111/risa.12265. <https://www.ncbi.nlm.nih.gov/pubmed/25109229>
15. Thompson KM, Cochi SL. Modeling and managing the risks of measles and rubella: a global perspective, part I. *Risk Anal* 2016; 36(7): 1288-96. doi:10.1111/risa.12655. <https://www.ncbi.nlm.nih.gov/pubmed/27424287>
16. Thompson KM. Evolution and use of dynamic transmission models for measles and rubella risk and policy analysis. *Risk Anal* 2016; 36(7): 1383-403. doi:10.1111/risa.12637. <https://www.ncbi.nlm.nih.gov/pubmed/27277138>



17. Simons EA, Reef SE, Cooper LZ, Zimmerman L, Thompson KM. Systematic review of the manifestations of congenital rubella syndrome in infants and characterization of disability-adjusted life years (DALYs). *Risk Anal* 2016; 36(7): 1332-56. doi:10.1111/risa.12263. <https://www.ncbi.nlm.nih.gov/pubmed/25115193>
18. Rota PA, Moss WJ, Takeda M, de Swart RL, Thompson KM, Goodson JL. Measles. *Nat Rev Dis Primers* 2016; 2: 16049. doi:10.1038/nrdp.2016.49. <https://www.ncbi.nlm.nih.gov/pubmed/27411684>
19. Thompson KM, Strebel PM, Dabbagh A, Cherian T, Cochi SL. Enabling implementation of the global vaccine action plan: developing investment cases to achieve targets for measles and rubella prevention. *Vaccine* 2013; 31 Suppl 2: B149-56. doi:10.1016/j.vaccine.2012.11.091. <https://www.ncbi.nlm.nih.gov/pubmed/23598476>
20. Thompson KM, Dabbagh A, Strebel PM, Perry R, Gacic-Dobo M, Cochi SL, Cairns L, Reef S. National and global options for managing the risks of measles and rubella. *J Vaccines Vaccin* 2012; 3: 165. doi:10.4172/2157-7560.1000165. <https://www.longdom.org/open-access/national-and-global-options-for-managing-the-risks-of-measles-and-rubella-2157-7560.1000165>
21. Goodson JL, Chu SY, Rota PA, Moss WJ, Featherstone DA, Vijayaraghavan M, Thompson KM, Martin R, Reef S, Strebel PM. Research priorities for global measles and rubella control and eradication. *Vaccine* 2012; 30(32): 4709-16. doi:10.1016/j.vaccine.2012.04.058. <https://www.ncbi.nlm.nih.gov/pubmed/22549089>